United Kingdom-based GW Pharmaceuticals expects to report annual sales of roughly $526 million for the yr ended Dec. 31, 2020, it stated in a preview of its fourth quarter and full-year outcomes.
Fourth quarter internet sales might be roughly $148 million, based mostly on preliminary unaudited monetary data, GW stated in a information launch this week.
Epidiolex, its most profitable product, accounts for a lot of the income.
Sales of Epidiolex are anticipated to be round $144 million for the quarter, comprising $129 million within the United States and $15 million outdoors the U.S.
The firm stated whole sales of Epidiolex for the fiscal yr are anticipated to be roughly $510 million, 41% greater than in 2019.
Cash and money equivalents as of Dec. 31, 2020 have been roughly $486 million.
“Our goals in 2021 include driving further Epidiolex growth and advancing multiple US pivotal trials for nabiximols in the treatment of MS spasticity, with the first data readout expected this year,” CEO Justin Gover stated within the information launch.
GW expects to report its fourth quarter and full-year ends in mid-February.
The firm’s shares commerce on the Nasdaq as GWPH.